Skip to content

Study · Randomized controlled trial · n = 36 · 2018

8 results

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.

Tonneijck L, Muskiet MHA, Smits MM, Bjornstad P, Kramer MHH, Diamant M, Hoorn EJ, Joles JA, van Raalte DH

Diabetes, obesity & metabolism20 Feb 2018Cited by 33 (Europe PMC)

PMID29341461 (opens in a new tab)PMCIDPMC5899927 (opens in a new tab)DOI10.1111/dom.13223 (opens in a new tab)PepBankPUB-29341461
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight adults with type 2 diabetes, 12 weeks of liraglutide did not change plasma uric acid compared with placebo.

    In plain wordsIn overweight adults with type 2 diabetes, 12 weeks of liraglutide did not change blood uric acid compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changePlasma uric acid
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In Study-C, liraglutide treatment did not affect plasma UA
    1 context sentence
    Summary · context
    The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight adults with type 2 diabetes, 12 weeks of liraglutide did not change urinary uric acid excretion compared with placebo.

    In plain wordsIn overweight adults with type 2 diabetes, 12 weeks of liraglutide did not change uric acid in urine compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeUrinary uric acid excretion (UE UA)
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In Study-C, liraglutide treatment did not affect plasma UA, UEUA, UENa or urine pH, compared to placebo.
    1 context sentence
    Summary · context
    The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight adults with type 2 diabetes, 12 weeks of liraglutide did not change urinary sodium excretion compared with placebo.

    In plain wordsIn overweight adults with type 2 diabetes, 12 weeks of liraglutide did not change sodium in urine compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeUrinary sodium excretion (UE Na)
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In Study-C, liraglutide treatment did not affect plasma UA, UEUA, UENa or urine pH, compared to placebo.
    1 context sentence
    Summary · context
    The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight adults with type 2 diabetes, 12 weeks of liraglutide did not change urine pH compared with placebo.

    In plain wordsIn overweight adults with type 2 diabetes, 12 weeks of liraglutide did not change urine acidity compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeUrine pH
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    In Study-C, liraglutide treatment did not affect plasma UA, UEUA, UENa or urine pH, compared to placebo.
    1 context sentence
    Summary · context
    The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined.
  5. 05HumanNon-randomized trialActivity measurement

    In overweight patients with type 2 diabetes, lixisenatide increased urinary sodium excretion from baseline.

    In plain wordsIn overweight patients with diabetes, urinary sodium excretion increased during lixisenatide treatment compared with baseline.

    Peptide
    Lixisenatide
    Outcome
    IncreaseUrinary sodium excretion
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    In Study-D, lixisenatide treatment increased UENa and urine pH from baseline, but did not affect plasma UA or UEUA .
    1 context sentence
    Summary · context
    The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined.
  6. 06HumanNon-randomized trialActivity measurement

    In overweight patients with type 2 diabetes, lixisenatide increased urine pH from baseline.

    In plain wordsIn overweight patients with diabetes, urine pH increased during lixisenatide treatment compared with baseline.

    Peptide
    Lixisenatide
    Outcome
    IncreaseUrine pH
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    In Study-D, lixisenatide treatment increased UENa and urine pH from baseline, but did not affect plasma UA or UEUA .
    1 context sentence
    Summary · context
    The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined.
  7. 07HumanNon-randomized trialActivity measurement

    In overweight patients with type 2 diabetes, lixisenatide did not affect plasma uric acid from baseline.

    In plain wordsIn overweight patients with diabetes, blood uric acid did not change during lixisenatide treatment compared with baseline.

    Peptide
    Lixisenatide
    Outcome
    No significant changePlasma uric acid
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    In Study-D, lixisenatide treatment increased UENa and urine pH from baseline, but did not affect plasma UA or UEUA .
    1 context sentence
    Summary · context
    The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined.
  8. 08HumanNon-randomized trialActivity measurement

    In overweight patients with type 2 diabetes, lixisenatide did not affect urinary uric acid excretion from baseline.

    In plain wordsIn overweight patients with diabetes, urinary uric acid excretion did not change during lixisenatide treatment compared with baseline.

    Peptide
    Lixisenatide
    Outcome
    No significant changeUrinary uric acid excretion
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    In Study-D, lixisenatide treatment increased UENa and urine pH from baseline, but did not affect plasma UA or UEUA .
    1 context sentence
    Summary · context
    The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 3

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.